Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
Rhea-AI Summary
Cellectar Biosciences (NASDAQ: CLRB) announced acceptance of a poster on CLOVER WaM subset data for relapsed/refractory Waldenström macroglobulinemia (r/r WM) to be presented at ASCO 2026 in Chicago.
The poster (No. 592) titled “Iopofosine I-131 after BTK inhibitors in Waldenström macroglobulinemia: CLOVER-WaM subgroup efficacy and safety” will be presented by Jarrod Longcor on June 1, 2026, 9:00 AM–12:00 PM CDT and highlights efficacy and safety results for patients treated immediately after BTK inhibitor therapy.
Positive
- None.
Negative
- None.
News Market Reaction – CLRB
In the Apr 21 session, CLRB declined 3.73%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Phase 1b enrollment | Positive | +7.7% | First patient enrolled in CLR 125 Phase 1b TNBC trial with supportive preclinical data. |
| Oct 14 | Preclinical poster data | Positive | +1.6% | Promising CLR 225 preclinical results in pancreatic models presented at AACR conference. |
| Jun 24 | Trial protocol filing | Positive | +8.6% | CLR 125 Phase 1b TNBC protocol submitted to FDA for 45-patient dose-finding study. |
| Jun 11 | CLOVER-2 pediatric data | Positive | +16.6% | CLOVER-2 pediatric pHGG data showed improved PFS/OS and tolerability for iopofosine I 131. |
| Dec 10 | Strategic restructuring | Negative | -76.2% | Strategic shift and ~60% headcount reduction to extend cash runway and refocus pipeline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial and data updates have generally led to price moves aligned with the news tone, including one severe selloff following a negative strategic update.
Over the last six months, Cellectar has reported multiple clinical milestones, including CLOVER and CLR 125 program advances and promising preclinical data across indications. A December 2024-12-10 restructuring and strategic update triggered a sharp selloff, while subsequent clinical trial headlines on 2025-06-11, 2025-06-24, 2025-10-14, and 2026-04-14 saw positive reactions. Today’s ASCO-focused CLOVER WaM subset presentation fits this pattern of data-centric communications around iopofosine I 131 and the broader pipeline.
Key Terms
Waldenström Macroglobulinemia medical
BTK inhibitors medical
salvage therapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
To Highlight Efficacy Results from Relapsed or Refractory Waldenström Macroglobulinemia Patients Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Society of Clinical Oncology Annual Meeting taking place May 29 - June 2 in Chicago, Illinois.
“We are pleased to share data from this important subset of r/r WM patients for whom there are no approved therapies and remaining options are restricted to salvage therapies which provide limited benefit. It is important to note that approximately
Details of the poster presentation are as follows:
| Title: | “Iopofosine I-131 after BTK inhibitors in Waldenström macroglobulinemia: CLOVER-WaM subgroup efficacy and safety” |
| Poster: | 592 |
| Date/Time: | June 1, 2026, 9:00 AM-12:00 PM CDT |
| Presenter: | Jarrod Longcor |
About Waldenstrom’s Macroglobulinemia
Waldenstrom’s Macroglobulinemia (WM) is a B-cell malignancy characterized by bone marrow infiltration with clonal lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM) that remains incurable with available treatments. The prevalence in the US is approximately 26,000 with 1,500–1,900 patients being diagnosed annually. Approximately 11,500 patients require treatment in the relapsed or refractory setting and there are an estimated 4,700 patients requiring third line or greater therapy. There are also approximately 1,000 patients that have exhausted all current treatment options by third line because they are ineligible or intolerant to those existing therapies. Therefore, the total addressable market for third line or greater therapy is approximately 5,700 patients. There are no U.S. Food and Drug Administration (FDA) approved treatment options for patients progressing on BTKi therapy. BTKi therapies do not demonstrate complete response rates and require continuous treatment.
Non-FDA approved treatments are used in more than
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b study is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation.
Cellectar is also developing CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b study for TNBC, which will determine the recommended dose for the subsequent Phase 2 trial. CLR 125 has been well tolerated in vivo and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth.
In addition to these assets, the Cellectar team is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit https://www.cellectar.com/ or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.
Forward Looking Statements Disclaimer
This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2025. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
INVESTORS:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
